Gsk annual report 2022 ventolin europe sales?

Ventolin Sales in Europe for GSK in 2022

GlaxoSmithKline (GSK) reported global sales of its respiratory products, including Ventolin, totaling £5.02 billion in 2022 [1]. The company's annual report for 2022 does not break down Ventolin's sales specifically for Europe [1]. However, GSK's respiratory franchise as a whole saw growth in emerging markets, contributing to overall performance [1].

What Does GSK's Respiratory Portfolio Include?

GSK's respiratory business encompasses a range of inhaled medicines used to treat conditions such as asthma and chronic obstructive pulmonary disease (COPD) [1]. These products target different mechanisms within the respiratory system to manage symptoms and improve lung function [1]. Ventolin, a short-acting beta-agonist (SABA), is a key medication within this category, providing rapid relief from bronchospasm [2].

How is Ventolin Regulated?

Ventolin, like other pharmaceutical products, is subject to regulatory approval and oversight in European countries [3]. Marketing authorization is granted by national regulatory agencies or the European Medicines Agency (EMA) for products intended for use across the European Union [3]. Post-market surveillance ensures ongoing safety and efficacy [3].

What are the Next Steps for GSK's Respiratory Business?

GSK is investing in the development of next-generation respiratory treatments, including biologics and innovative inhaler technologies [1]. The company aims to address unmet needs in severe asthma and other respiratory diseases [1]. This focus on innovation is part of GSK's strategy to strengthen its position in the respiratory market [1].

---
Sources

1. GlaxoSmithKline. (2023). Annual Report and Strategic Update 2022. https://www.gsk.com/media/785231/gsk-annual-report-2022.pdf
2. DrugPatentWatch. (n.d.). Ventolin. Retrieved from https://drugpatentwatch.com/
3. European Medicines Agency. (n.d.). Medicines. Retrieved from https://www.ema.europa.eu/en/human-medicines